Claudio Cobelli (Italy)
University of Padova
Department of Woman and Child’s Health
Claudio Cobelli is Emeritus Professor of Bioengineering, University of Padova. From 2000 to 2011 he has been Chairman of the Graduate Program in Biomedical Engineering and the Ph.D. Program in Bioengineering at the University of Padova. His research activity is in modeling and technology of diabetes. His research is supported by NIH, JDRF and European Comunity. He has published 743 papers in internationally refereed journals http://www.ncbi.nlm.nih.gov/pubmed/?term=cobelli%20c (co-author of 8 books and holds 10 patents with an h-index of 90, citations 34486 (Scopus). He is Associate Editor of IEEE Transaction on Biomedical Engineering and Journal of Diabetes Science & Technology, and on the Editorial Board of Diabetes Technology & Therapeutics. Dr.Cobelli has been Chairman (1999-2004) of the Italian Bioengineering Group, Chairman (1990-1993 & 1993-1996) of IFAC TC on Modeling and Control of Biomedical Systems. In 2010 he received the Diabetes Technology Artificial Pancreas Research Award. He is Fellow of IEEE and BMES.

Presenter of 1 Presentation

 Conference Calendar

A Bionic Fully Automated Intraperitoneal Insulin Delivery System: the EU Project FORGETDIABETES

Session Name
0790 - PARALLEL SESSION - ADVANCED TECHNOLOGIES AND REGULATORY ADJUSTMENTS IN TREATING DIABETES (ID 55)
Session Type
Parallel Session
Date
Sat, 30.04.2022
Session Time
13:00 - 14:30
Room
Hall 113
Presenter
Lecture Time
13:00 - 13:20

Abstract

Abstract Body

The last decade has seen important developments in closed-loop subcutaneous (sc) sensing and insulin delivery closed-loop systems. However major limitations of subcutaneous insulin delivery still exist, including the hyper-insulinemia due to the non-physiologic sc route and need for meal announcement. FORGETDIABETES introduces a radically new approach to Type 1 Diabetes (T1D) treatment, by developing a fully-implantable, fully-automated bionic invisible pancreas (BIP) based on physiological intraperitoneal (ip) hormone delivery, thus enabling an optimal glycemic control. BIP will free individuals with T1D from therapeutic actions and from the related psychological burden. BIP will become a life-condition (like contact lens), allowing T1D patients to live just as everybody else. An interdisciplinary team with top experts in micronano mechatronics, control engineering, biomaterials, endocrinology, surgery and behavioral sciences has been assembled to develop a long-lasting system relying on a physiological glucose sensing and hormone delivery, orchestrated by personalized adaptive algorithms with advanced self-diagnostic capabilities. Pump refilling through a weekly oral recyclable drug pill will free T1D subjects from the burden of treatment actions. Wireless power transfer and data transmission to cloud-based data management system round-up to a revolutionary treatment device for this incurable chronic disease. In this project, the key technologies enabling BIP will be developed. Furthermore, extensive in vivo preclinical experiments along with massive in silico testing will establish the prototype system, paving the way to the ambitious first-in-human inpatient trial of BIP. This paradigm will revolutionize diabetes treatment and stimulate an innovation ecosystem including research bodies, SMEs, patient organizations, diabetes societies and clinicians.
Hide